Bringing the very best science and medicine to our best equine friends
March 2017

Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit

San Francisco, CA (March 16, 2017) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Dr. Richard Chin, Chief Executive Officer, will be presenting at the 2017 Jefferies Animal Health Summit in New York, NY on Thursday, March 30, 2017 at 10:45 AM EDT. This conference will not be webcast.  Investors and other interested parties may access the corporate presentation following this meeting at http://kindredbio.com/jefferies2017. About Kindred Biosciences Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to …

Continue Reading

Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotion Pathology

San Francisco, CA (March 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is proud to announce its partnership with the International Society of Equine Locomotion Pathology (ISELP) by joining their team of Global Sponsors starting in 2017. The partnership with ISELP is part of an initiative by KindredBio to support the education of veterinarians and veterinary students, and to promote the growth and advancement of the equine industry. ISELP is an advanced education program for equine veterinarians to learn the most advanced techniques in diagnostics and treatments for the …

Continue Reading

Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results

San Francisco, CA (March 1, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016. “We are very pleased with the progress of Mirataz™ and Zimeta™, including the recently announced approval of the efficacy technical section for Mirataz,” stated Richard Chin, M.D., President and CEO of KindredBio. “We are looking forward to the transition to a commercial-stage company in 2017, with the anticipated approval and launch of two products in the second half of the year, …

Continue Reading